Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › brodalumab

brodalumab

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of brodalumab

6 trials tracked of brodalumab: 2 in phase 3 or 4.

6Trials tracked
2Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 2 Phase 2 2 Phase 1 2
  1. Phase 4 Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies Completed
  2. Phase 4 A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis Completed
  3. Phase 2 Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid Arthritis Completed
  4. Phase 2 Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate Completed
  5. Phase 1 Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects Completed
  6. Phase 1 A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Guselkumab, Secukinumab, and Brodalumab rank highly for PASI 75 and PASI 90 in plaque psoriasis
Oncology Meta-analysis
Guselkumab, Secukinumab, and Brodalumab rank highly for PASI 75 and PASI 90 in plaque psoriasis New data ranks different treatments for moderate to severe psoriasis
This systematic review and network meta-analysis of 27 RCTs evaluated IL-23/IL-17 inhibitors for moderate-to-severe plaque psoriasis. Guselk…
Comparing several types of biologics helps patients with plaque psoriasis find which medications rank highest for clearing skin and improvin…
Frontiers Jul 26, 2026
IL-17 inhibitors rank highly for clearance of scalp, nail, and palmoplantar psoriasis
Dermatology Meta-analysis
IL-17 inhibitors rank highly for clearance of scalp, nail, and palmoplantar psoriasis Biologics Show Different Success Rates for Scalp and Nail Psoriasis
This network meta-analysis of 5,946 patients evaluated IL-17/IL-23 axis biologics for difficult-to-treat psoriasis sites. The analysis found…
Different biologics show varying success rates for clearing psoriasis on the scalp, nails, and palms based on a large network analysis.
Frontiers Jul 23, 2026
Brodalumab Improves Palmoplantar Pustulosis in Japanese Adults in Phase 3 Trial
Dermatology RCT
Brodalumab Improves Palmoplantar Pustulosis in Japanese Adults in Phase 3 Trial Brodalumab shows benefit for palmoplantar pustulosis in Japanese adults
This randomized Phase 3 trial in Japanese adults with palmoplantar pustulosis found that brodalumab 210 mg improved PPPASI scores similarly …
A Phase 3 trial found brodalumab improved skin scores for palmoplantar pustulosis in Japanese adults, though infection risks were frequent.
May 1, 2026